Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izaf302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Yu Nishida und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Pyrimidines, Piperidines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background and aims Patients with ulcerative colitis (UC) have an elevated thromboembolic risk. The comparative risks associated with advanced therapies (ADTs) remain unclear.
Methods
In this retrospective cohort study, we utilized the Japanese Medical Data Vision claims database to assess patients with UC who initiated treatment with tumor necrosis factor (TNF) inhibitors, vedolizumab, or tofacitinib. We evaluated the cumulative incidence and hazard ratios (HRs) for venous thromboembolisms (VTEs), cardiovascular events (CVEs), and major adverse cardiovascular events (MACEs). The tofacitinib dose was modeled as a time-varying covariate.
Results
In total, 8125 TNF inhibitor users, 1218 tofacitinib users, and 2469 vedolizumab users were analyzed. Compared with TNF inhibitors, vedolizumab was associated with a lower risk of VTE (HR ,50, 95% CI 0.30-0.81) and CVE (HR 0.47, 95% CI, 0.27-0.81), with no difference in MACE. Tofacitinib 5 mg and 10 mg administration twice daily (BID) showed no significant differences vs TNF inhibitors, though point estimates were lower at 5 mg and higher at 10 mg. Concomitant 5-aminosalicylic acid was associated with a lower incidence of VTE.
Conclusions
Vedolizumab demonstrated a favorable thromboembolic and cardiovascular safety profile compared with TNF inhibitors, whereas tofacitinib did not increase the risk at either dose. Concomitant 5-aminosalicylic acid may have a preventive effect against VTE. These findings may aid therapeutic decision-making for UC patients with elevated thrombotic risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
ORCID-Profile: Yu Nishida, Shuhei Hosomi
Zitieren
APA
Nishida, Y., Hosomi, S., Fujimoto, K., Kobayashi, Y., Nakata, R., Maruyama, H., Ominami, M., Nadatani, Y., Fukunaga, S., Otani, K., Tanaka, F., & Fujiwara, Y. (2026). Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf302
Vancouver
Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, et al. Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf302
BibTeX
@article{Nishida2026,
author = {Nishida, Yu and Hosomi, Shuhei and Fujimoto, Koji and Kobayashi, Yumie and Nakata, Rieko and Maruyama, Hirotsugu and Ominami, Masaki and Nadatani, Yuji and Fukunaga, Shusei and Otani, Koji and Tanaka, Fumio and Fujiwara, Yasuhiro},
title = {Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izaf302}
}
EUVIMED